Showing 1 - 5 results of 5 for search 'Joyce O'Shaughnessy', query time: 0.01s Refine Results
  1. 1
    Real-world risk of recurrence and treatment outcomes with adjuvant endocrine therapy in patients with stage II-III HR+/HER2- early breast cancer

    Real-world risk of recurrence and treatment outcomes with adjuvant endocrine therapy in patients with stage II-III HR+/HER2- early breast cancer by Joyce O'Shaughnessy, Sara M. Tolaney, Denise A. Yardley, Lowell Hart, Pedram Razavi, Peter A. Fasching, Wolfgang Janni, Lee Schwartzberg, Julia Kim, Murat Akdere, Courtney McDermott, Aamir Khakwani, Purnima Pathak, Stephanie L. Graff

    Published 2025-06-01
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    TROPION-Breast05: a randomized phase III study of Dato-DXd with or without durvalumab versus chemotherapy plus pembrolizumab in patients with PD-L1-high locally recurrent inoperable or metastatic triple-negative breast cancer

    TROPION-Breast05: a randomized phase III study of Dato-DXd with or without durvalumab versus chemotherapy plus pembrolizumab in patients with PD-L1-high locally recurrent inoperabl... by Peter Schmid, Mafalda Oliveira, Joyce O’Shaughnessy, Massimo Cristofanilli, Stephanie L. Graff, Seock-Ah Im, Sherene Loi, Shigehira Saji, Shusen Wang, David W. Cescon, Tina Hovey, Agata Nawrot, Karson Tse, Petra Vukovic, Giuseppe Curigliano

    Published 2025-04-01
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    Five‐year results of a phase II trial of preoperative 5‐fluorouracil, epirubicin, cyclophosphamide followed by docetaxel with capecitabine (wTX) (with trastuzumab in HER2‐positive patients) for patients with stage II or III breast cancer

    Five‐year results of a phase II trial of preoperative 5‐fluorouracil, epirubicin, cyclophosphamide followed by docetaxel with capecitabine (wTX) (with trastuzumab in HER2‐positive... by Frankie Ann Holmes, Beth A. Hellerstedt, John E. Pippen Jr., Svetislava J. Vukelja, Rufus P. Collea, Darren M. Kocs, Joanne L. Blum, Kristi J. McIntyre, Minal A. Barve, Barry D. Brooks, Cynthia R. Osborne, Yunfei Wang, Lina Asmar, Joyce O'Shaughnessy

    Published 2018-06-01
    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    Author Correction: Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib

    Author Correction: Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib by R. C. Coombes, Sacha Howell, Simon R. Lord, Laura Kenny, Janine Mansi, Zahi Mitri, Carlo Palmieri, Linnea I. Chap, Paul Richards, William Gradishar, Sagar Sardesai, Jason Melear, Joyce O’Shaughnessy, Patrick Ward, Pavani Chalasani, Tobias Arkenau, Richard D. Baird, Rinath Jeselsohn, Simak Ali, Glen Clack, Ashwani Bahl, Stuart McIntosh, Matthew G. Krebs

    Published 2025-03-01
    Get full text
    Article
    Save to List
    Saved in:
  5. 5
    Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib

    Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib by R. C. Coombes, Sacha Howell, Simon R. Lord, Laura Kenny, Janine Mansi, Zahi Mitri, Carlo Palmieri, Linnea I. Chap, Paul Richards, William Gradishar, Sagar Sardesai, Jason Melear, Joyce O’Shaughnessy, Patrick Ward, Pavani Chalasani, Tobias Arkenau, Richard D. Baird, Rinath Jeselsohn, Simak Ali, Glen Clack, Ashwani Bahl, Stuart McIntosh, Matthew G. Krebs

    Published 2023-07-01
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: